



ASH 2025

67th ASH Annual Meeting and Exposition

December 6–9, 2025
Orlando, United States



TOP ABSTRACTS

To help navigate the exciting content being presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in acute myeloid leukemia.

ASH 2025: Top abstracts in acute myeloid leukemia

December 6–9, 2025

Oral presentations: Saturday, December 6

Abstract	Title	Presenter	Time (EST)
42 View	Outcomes of patients with relapsed/refractory <i>FLT3</i> mut+ acute myeloid leukemia who resumed gilteritinib therapy after HSCT: <i>Post hoc</i> analysis from the ADMIRAL and COMMODORE trials	Jianxiang Wang	10:45–11:00
45 View	Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed <i>FLT3</i> -mutated acute myeloid leukemia	Roberta S Azevedo	10:00–10:15
47 View	Phase II study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML	Wei-Ying Jen	10:30–10:45
109 View	Superior long-term outcomes with fludarabine and melphalan reduced intensity regimen in older AML/MDS patients undergoing allogeneic stem cell transplantation: An analysis of CIBMTR data	Piyanuch Kongtim	09:30–09:45
110 View	Addition of thiotepea to a busulphan based conditioning regimen does not improve survival in patients allografted for acute myeloid leukaemia and myelodysplasia: Results of the UK impact COSI trial	Charles Craddock	09:45–10:00
170 View	Effect of <i>FLT3</i> maintenance in older <i>FLT3</i> -ITD+ adults undergoing allogeneic HCT. A <i>post hoc</i> analysis of BMT CTN 1506	Sameem Abedin	12:15–12:30
344 View	Prospective assessment of measurable residual disease kinetics in intensively treated patients with acute myeloid leukemia (AML) - results of the PALG-AML1/2016 study	Agnieszka Wierzbowska	16:15–16:30
345 View	<i>FLT3</i> -ITD NGS-MRD refines risk stratification in <i>NPM1</i> and <i>FLT3</i> co-mutated AML beyond <i>NPM1</i> PCR-MRD: Analysis of the UK NCRI AML17 and AML19 trials	Aditya Tedjaseputra	16:30–16:45

Oral presentations: Sunday, December 7

Abstract	Title	Presenter	Time (EST)
6 View	Results from PARADIGM - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia	Amir Fathi	15:45–16:00
652 View	γ9δ2 T-cell (γ9δ2TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): Results from the phase 1/2 study EVICTION	Sylvain Garciaz	17:15–17:30
654 View	Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) <i>FLT3</i> mut+ acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study	Jessica Altman	17:45–18:00

Oral presentations: Monday, December 8

Abstract	Title	Presenter	Time (EST)
763 View	Monotherapy update from phase 1 portion in phase 1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia	Naval Daver	10:30–10:45
764 View	Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory <i>NPM1</i> -m or <i>KMT2A</i> -r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007	Amir Fathi	11:45–12:00
765 View	Preliminary data from the ongoing phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory acute myeloid leukemia	Justin Watts	11:00–11:15
766 View	Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed <i>NPM1</i> -m acute myeloid leukemia: Phase 1b results from KOMET-007	Gail Roboz	11:15–11:30
767 View	Crenolanib plus salvage chemotherapy improves outcomes in <i>FLT3</i> -mutant and <i>NPM1</i> co-mutated relapsed/ refractory (R/R) acute myeloid leukemia (AML): Results from a randomized, placebo-controlled, double-blind trial	Thomas Cluzeau	11:30–11:45
768 View	Preliminary anti-leukemia activity from a phase 1 study of CLN-049, a novel anti- <i>FLT3</i> x anti-CD3 bispecific T-cell engager, in relapsed/refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)	Maher Abdul-Hay	10:45–11:00
992 View	Updated response and safety analyses from a phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) acute myeloid leukemia with isocitrate dehydrogenase (<i>IDH</i>)1 mutation	Eytan Stein	16:45–17:00

Posters

Abstract	Title	Presenter	Date and time (EST)
1507 View	<i>PPM1D</i> mutations confer resistance to venetoclax in pre-leukemic and AML populations	Jules Higue	Saturday, December 6, 17:30–19:30
1662 View	Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory <i>FLT3</i> -mutated acute myeloid leukemia: A European multicenter study of 171 patients	Matteo Molica	Saturday, December 6, 17:30–19:30
2650 View	Healthcare resource utilization in patients receiving quizartinib or placebo in combination with chemotherapy for newly diagnosed, <i>FLT3</i> -ITD+ acute myeloid leukemia: An analysis from the QuANTUM-first trial	Harry Erba	Saturday, December 6, 17:30–19:30

3428 View	Phase I dose escalation and expansion of ziftomenib in combination with quizartinib in AML	Ghayas Issa	Sunday, December 7, 18:00–20:00
3439 View	Analysis of hematologic improvement (HI) by time to response in relapsed/refractory acute myeloid leukemia (AML) patients treated with olutasidenib	Eunice Wang	Sunday, December 7, 18:00–20:00
3440 View	CYP3A4 inhibitors (CYP3A4i) and myelosuppression in patients (pts) with newly diagnosed mutant isocitrate dehydrogenase 1 (<i>mIDH1</i>) acute myeloid leukemia (AML) in the phase 3 AGILE study	Andre Schuh	Sunday, December 7, 18:00–20:00
3443 View	ALIDHE: An ongoing open-label phase 3b study investigating ivosidenib with azacitidine in clinical practice in adult patients with newly diagnosed mutant isocitrate dehydrogenase 1 (<i>mIDH1</i>) acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy (IC)	Pareesh Vyas	Sunday, December 7, 18:00–20:00
3465 View	Identifying patients at risk of prolonged neutropenia and enhanced risk of complications during AZA-VEN induction for AML	Jules Higue	Sunday, December 7, 18:00–20:00
5067 View	A randomized placebo-controlled phase 1 trial in healthy volunteers investigating safety, pharmacokinetics and pharmacodynamics of a novel menin inhibitor, balomenib (ZE63-0302): Interim analysis	Amy Burd	Monday, December 8, 18:00–20:00
5215 View	Effectiveness and safety of CPX-351 in younger patients <60 years with newly diagnosed secondary acute myeloid leukemia: Pooled analysis of US (V-RULES) and UK (CREST-UK) real-world studies	Thomas LeBlanc	Monday, December 8, 18:00–20:00
5226 View	A phase II study of azacitidine, venetoclax, and gilteritinib for newly diagnosed adverse risk <i>FLT3</i> -wild type acute myeloid leukemia	Sankalp Arora	Monday, December 8, 18:00–20:00



#ASH25

Follow us on X to keep up to date
with the latest from the congress

@AML_Hub



Brought to you by

